Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.
Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111 USA.
Department of Otolaryngology-Head & Neck Surgery, Temple University School of Medicine, 3401 North Broad Street, Kresge West, Philadelphia, PA 19140 USA.
- Published Article
Journal for ImmunoTherapy of Cancer
Springer (Biomed Central Ltd.)
- Publication Date
Jan 01, 2016
Autoimmune inner ear disease has been previously associated with the therapeutic transfer of genetically engineered lymphocytes as an on-target effect of donor T-cells recognizing antigens on cells in the inner ear. It is important for physicians to have a high clinical index of suspicion for the appropriate recognition and management of any potential autoimmune toxicity with checkpoint inhibitors given the variability of presentation and unique aspects of toxicity.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/26885370